BerlinBioCube Entwurf

Cornerstone laid for BerlinBioCube

There is strong demand for laboratories, and biotech entrepreneurs need space in state-of-the-art research facilities. Now, in the presence of Berlin’s Governing Mayor, the cornerstone for the new BerlinBioCube incubator has been laid on Campus Berlin-Buch.

A new incubator is being built at BiotechPark Berlin-Buch for start-ups that want to turn promising therapeutics and diagnostics into new medical solutions. Starting in 2023, the five-story BerlinBioCube will offer around 8,000 square meters of space for modern laboratories, offices and communal areas. The forward-looking project will create up to 400 new jobs on the biomedical campus – one of the leading science and technology locations in Germany.

At the cornerstone-laying ceremony, Berlin’s Governing Mayor and Senator for Higher Education and Research Michael Müller stressed in his speech: “Campus Berlin-Buch is growing more and more into a powerhouse for our medical and biotech industry. The interaction here between strong research institutions and innovative companies is creating great potential, and the new BerlinBioCube incubator will enable us to tap into this potential even more. This important investment lays another foundation stone for sustainable economic growth and supports the creation of new recession-proof jobs. Successful cooperation between science and business is the best way to ensure that our city thrives in the future.”

The ceremony was also attended by Pankow’s District Mayor Sören Benn, and the managing directors of Campus Berlin-Buch GmbH, Dr. Christina Quensel and Dr. Ulrich Scheller. Architect Rainer Post delivered a video message.

For northern Berlin, a very positive signal

Pankow’s District Mayor Sören Benn said: “The campus already offers 3,000 jobs, most of which are highly-specialized and skilled positions. Promoting the campus’s economic growth, and the additional jobs that come along with that, is a hugely positive signal for future urban development in northern Berlin.”

Campus Manager Quensel emphasized that the BiotechPark is expanding at just the right time: “We are experiencing very high demand from young companies for laboratory space. Start-ups that are already established at the BiotechPark need more space, and inquiries from outside companies, including international ones, continue to come in. The campus’s profile is particularly attractive for start-ups in medical biotechnology, medical technology and related fields.”

The boxy building by doranth post architekten makes optimal use of the space it occupies in the BiotechPark. The structuring of the façade and textile elements give a greater lightness to the building.

As Rainer Post explained, the incubator meets the demands of state-of-the-art research facilities. These include high amenity value, laboratories with daylight, and common areas that foster and encourage communication.

The construction of the new BerlinBioCube involves an investment of €55 million and is made possible by funding from the Joint Task for the Improvement of Regional Economic Structures (GRW). The new incubator completes the BiotechPark. Areas close to the campus, which were defined in the framework plan for the southern section of Buch (Buch Süd), are slated for further expansion.

A video of the event will be available at .


BerlinBioCube facts and figures

Address:             BerlinBioCube, Robert-Rössle-Str. 10, 13125 Berlin

Client:                  Campus Berlin-Buch GmbH

Architect:          doranth post architekten GmbH

Total cost: €55 million

Floor space:       8,000 m2

Construction:    2020 – 2023

Link to the BerlinBioCube website


The construction of the BerlinBioCube incubator was funded under the Joint Task for the Improvement of Regional Economic Structures (GRW), a policy initiative of the federal and state governments to bolster regional economic growth.


Campus Berlin‐Buch


Campus Berlin‐Buch is a modern science, health and biotechnology park. The unique features of the campus include the clear focus on biomedicine and the proximity and close collaboration of research institutions, clinics and biotech companies. Research focuses on the molecular causes of cancer, cardiovascular and neurodegenerative diseases, while other areas include interdisciplinary basic research into developing new therapeutics and diagnostics, patient-oriented research and the commercialization of biomedical research results.

With its excellent research institutions and companies in the BiotechPark, Campus Berlin-Buch has outstanding innovation and growth potential. The Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), the Experimental and Clinical Research Center (ECRC) jointly run by the MDC and Charité – Universitätsmedizin Berlin, and the Berlin Institute of Health (BIH) are just some of the institutions conducting basic research here. Since 1992, more than €600 million of public funds from the EU, the German government and the State of Berlin have been invested in Campus Berlin-Buch in order to enhance these synergies.


BiotechPark Berlin‐Buch


With 67 companies, 800 employees and around 31,000 square meters of office and lab space, the BiotechPark in Berlin’s Buch neighborhood is one of Germany’s leading technology parks. Spin-offs in the life sciences sector will find ideal conditions here, from technology transfer services to industry-specific laboratory and office space. The local life science community enables direct exchange and joint projects. The BiotechPark makes a major contribution to the dynamic development of the Berlin-Brandenburg biotechnology region and particularly strengthens the industrial health economy.


Managing company of Campus Berlin-Buch


As the managing company of Campus Berlin-Buch, Campus Berlin-Buch GmbH is the partner for all companies and institutions located on campus. Its main tasks are to aid biotech companies – from start-ups to mature businesses – in settling on campus and to provide them with assistance and support. The shareholders of Campus Berlin-Buch GmbH are the State of Berlin (50.1%), the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) (29.9 %) and the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) (20 %).